Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) EPS (Weighted Average and Diluted): 2020-2024

Historic EPS (Weighted Average and Diluted) for BridgeBio Pharma (BBIO) over the last 5 years, with Dec 2024 value amounting to -$2.88.

  • BridgeBio Pharma's EPS (Weighted Average and Diluted) fell 10.47% to -$0.95 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.20, marking a year-over-year decrease of 74.27%. This contributed to the annual value of -$2.88 for FY2024, which is 27.09% up from last year.
  • As of FY2024, BridgeBio Pharma's EPS (Weighted Average and Diluted) stood at -$2.88, which was up 27.09% from -$3.95 recorded in FY2023.
  • Over the past 5 years, BridgeBio Pharma's EPS (Weighted Average and Diluted) peaked at -$2.88 during FY2024, and registered a low of -$3.95 during FY2023.
  • Its 3-year average for EPS (Weighted Average and Diluted) is -$3.36, with a median of -$3.26 in 2022.
  • In the last 5 years, BridgeBio Pharma's EPS (Weighted Average and Diluted) decreased by 21.17% in 2023 and then rose by 27.09% in 2024.
  • Over the past 5 years, BridgeBio Pharma's EPS (Weighted Average and Diluted) (Yearly) stood at -$3.80 in 2020, then fell by 2.63% to -$3.90 in 2021, then rose by 16.41% to -$3.26 in 2022, then dropped by 21.17% to -$3.95 in 2023, then grew by 27.09% to -$2.88 in 2024.